- Home
- IMCR vs ZLAB Comparison
IMCR vs ZLAB Comparison
Compare IMCR & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCR
- ZLAB
- Stock Information
- Founded
- IMCR 2008
- ZLAB 2013
- Country
- IMCR United Kingdom
- ZLAB China
- Employees
- IMCR N/A
- ZLAB N/A
- Industry
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- ZLAB Biotechnology: Pharmaceutical Preparations
- Sector
- IMCR Health Care
- ZLAB Health Care
- Exchange
- IMCR Nasdaq
- ZLAB Nasdaq
- Market Cap
- IMCR 1.5B
- ZLAB 3.6B
- IPO Year
- IMCR 2021
- ZLAB 2017
- Fundamental
- Price
- IMCR $32.80
- ZLAB $36.40
- Analyst Decision
- IMCR Buy
- ZLAB Buy
- Analyst Count
- IMCR 10
- ZLAB 5
- Target Price
- IMCR $58.13
- ZLAB $54.28
- AVG Volume (30 Days)
- IMCR 444.9K
- ZLAB 886.5K
- Earning Date
- IMCR 08-07-2025
- ZLAB 08-05-2025
- Dividend Yield
- IMCR N/A
- ZLAB N/A
- EPS Growth
- IMCR N/A
- ZLAB N/A
- EPS
- IMCR N/A
- ZLAB N/A
- Revenue
- IMCR $333,581,000.00
- ZLAB $418,326,000.00
- Revenue This Year
- IMCR $26.82
- ZLAB $44.07
- Revenue Next Year
- IMCR $8.15
- ZLAB $49.13
- P/E Ratio
- IMCR N/A
- ZLAB N/A
- Revenue Growth
- IMCR 25.75
- ZLAB 43.72
- 52 Week Low
- IMCR $23.15
- ZLAB $16.01
- 52 Week High
- IMCR $41.54
- ZLAB $44.34
- Technical
- Relative Strength Index (RSI)
- IMCR 51.47
- ZLAB 52.67
- Support Level
- IMCR $30.76
- ZLAB $34.79
- Resistance Level
- IMCR $33.95
- ZLAB $36.73
- Average True Range (ATR)
- IMCR 1.39
- ZLAB 1.23
- MACD
- IMCR -0.15
- ZLAB -0.46
- Stochastic Oscillator
- IMCR 43.05
- ZLAB 25.91
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.